---
figid: PMC6094610__mmt-02-199-g1
figtitle: Dabrafenib and its use in the treatment of metastatic melanoma
organisms:
- NA
pmcid: PMC6094610
filename: mmt-02-199-g1.jpg
figlink: /pmc/articles/PMC6094610/figure/F0001/
number: F1
caption: Activation of the MAPK pathway due to mutations in BRAF leads to increased
  proliferation and survival of melanoma cells. This growth pathway can be disrupted
  by targeted agents such as BRAF and MEK inhibitors.
papertitle: Dabrafenib and its use in the treatment of metastatic melanoma.
reftext: Samantha Bowyer, et al. Melanoma Manag. 2015 Aug;2(3):199-208.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9594967
figid_alias: PMC6094610__F1
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC6094610__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6094610__mmt-02-199-g1.html
  '@type': Dataset
  description: Activation of the MAPK pathway due to mutations in BRAF leads to increased
    proliferation and survival of melanoma cells. This growth pathway can be disrupted
    by targeted agents such as BRAF and MEK inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Trametinib
  - Dabrafenib
  - Cobimetinib
  - Binimetinib
  - tyrosine
---
